`5712727822
`
`Paper No. ___
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`ACTAVIS LABORATORIES FL, INC., AMNEAL
`PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW
`YORK, LLC, DR. REDDY’S LABORATORIES, INC., DR. REDDY’S
`LABORATORIES, LTD., SUN PHARMACEUTICALS INDUSTRIES,
`LTD., SUN PHARMACEUTICALS INDUSTRIES, INC., TEVA
`PHARMACEUTICALS USA, INC., WESTWARD PHARMACEUTICAL
`CORP., and HIKMA PHARMACEUTICALS, LLC
`Petitioners
`
`v.
`
`JANSSEN ONCOLOGY, INC
`Patent Owner
`____________
`
`Case IPR201700853
`Patent 8,822,438
`____________
`
`
`
`Trials@uspto.gov
`5712727822
`
`Paper No. ___
`
`Mailed: March 8, 2017
`
`Before GREEN T.D., Trial Paralegal
`
`NOTICE OF FILING DATE ACCORDED TO PETITION
`AND
`TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE
`
`The petition for inter partes review in the above proceeding has been
`accorded the filing date of February 8, 2017.
`A review of the petition identified the following defect(s):
`
`The file uploaded as “Exhibit 1029” does not conform with the
`requirements for papers 37 C.F.R. § 42.63(d)(1)(i). Specifically, Ex. 1029 is
`
`labeled as Ex. 1028.
`Petitioner must correct the defect(s) within FIVE BUSINESS DAYS
`from this notice. Failure to correct the defect(s) may result in an order to
`show cause as to why the Board should institute the trial. No substantive
`
`changes (e.g., new grounds) may be made to the petition.
`Patent Owner may file a preliminary response to the petition no later
`
`than three months from the date of this notice. The preliminary response is
`limited to setting forth the reasons why the requested review should not be
`
`instituted. Patent Owner may also file an election to waive the preliminary
`response to expedite the proceeding. For more information, please consult
`
`
`
`Case
`Patent No.
`
`the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012),
`which is available on the Board Web site at http://www.uspto.gov/PTAB.
`
`Patent Owner is advised of the requirement to submit mandatory
`notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of
`
`the petition.
`The parties are encouraged to use the heading on the first page of this
`
`Notice for all future filings in the proceeding.
`The parties are advised that under 37 C.F.R. § 42.10(c), recognition of
`
`counsel pro hac vice requires a showing of good cause. The parties are
`
`authorized to file motions for pro hac vice admission under 37 C.F.R.
`
`§ 42.10(c). Such motions shall be filed in accordance with the “Order
`
`Authorizing Motion for Pro Hac Vice Admission” in Case IPR201300639,
`
`Paper 7, a copy of which is available on the Board Web site under
`“Representative Orders, Decisions, and Notices.”
`
`The parties are reminded that unless otherwise permitted by 37 C.F.R.
`§ 42.6(b)(2), all filings in this proceeding must be made electronically in
`
`Patent Trial and Appeal Board End to End (PTAB E2E), accessible from the
`Board Web site at http://www.uspto.gov/PTAB. To file documents, users
`
`must register with PTAB E2E. Information regarding how to register with
`and use PTAB E2E is available at the Board Web site.
`
`If there are any questions pertaining to this notice, please contact T.D.
`Green at 5712720327 or the Patent Trial and Appeal Board at 571272
`
`7822.
`
`3
`
`
`
`Case
`Patent No.
`
`PETITIONER:
`
`Actavis Laboratories FL Inc.
`Morris Corporate Center III
`400 Interpace Parkway
`Parsippany, NJ 07054
`
`Hikma Pharmaceuticals LLC
`Bayader Wadi Sheer
`P.O. Box 182400
`Amman, 1118, JO
`
`PATENT OWNER:
`Janssen Oncology, Inc.
`10990 Wilshire Blvd
`Suite 1200
`Los Angeles, CA 90024
`
`4
`
`
`
`Case
`Patent No.
`
`Johnson & Johnson
`Attn: Joseph F. Shirtz
`One Johnson & Johnson Plaza
`New Brunswick, NJ 089337003
`
`5
`
`